Although is produced by various leukocytes, it preferentially targets cells with epithelial origins. IL-22 exerts essential roles in modulating various tissue epithelial functions, such as innate host defense against extracellular pathogens, barrier integrity, regeneration, and wound healing. Therefore, IL-22 is thought to have therapeutic potential in treating diseases associated with infection, tissue injury or chronic tissue damage. A number of in vitro and in vivo nonclinical studies were conducted to characterize the pharmacological activity and safety parameters of UTTR1147A, an IL-22 recombinant fusion protein that links the human cytokine IL-22 with the Fc portion of a human immunoglobulin. To assess the pharmacological activity of UTTR1147A, STAT3 activation was evaluated in primary hepatocytes isolated from human, cynomolgus monkey, minipig, rat, and mouse after incubation with UTTR1147A. UTTR1147A activated STAT3 in all species evaluated, demonstrating that all were appropriate nonclinical species for toxicology studies.
| INTRODUCTION
Interleukin 22 belongs to the IL-10 cytokine family 1 and binds specifically to the IL-22 receptor (IL-22R), a heterodimeric complex consisting of an IL-22R and an IL-10R2 chain. 2 While IL-10R2 chain is ubiquitously expressed, the IL-22RA1 chain is preferentially expressed on a variety of cells with epithelial origins tissues, including epidermal keratinocytes, the gastrointestinal (GI) tract epithelium, liver hepatocytes, pancreatic epithelium, and renal tubular epithelium. 3 involved in host defense, 4 ,5 inflammation, 6, 7 and repair, 8 there is also evidence to suggest that an activation of the IL-22 pathway may induce or exacerbate inflammatory processes in psoriasis and in arthritis. 7, [9] [10] [11] IL-22 induces the expression of mucus-associated molecules and the restitution of mucus-producing goblet cells. 12 In addition, IL-22 increases the production of antimicrobial peptides, 5, 12 which is essential for host defense against various pathogens and leads to modulation of the colonic microflora. 5, 13 IL-22 also increases epithelial proliferation and repair of the epithelial barrier 8, 14, 15 and elevated systemic levels of IL-22 appear to have a protective effect against mucosal damage. Evidence for IL-22′s role in wound healing comes from its ability to stimulate keratinocyte proliferation to accelerate re-epithelialization, induce local vascular endothelial growth factor (VEGF) production to increase neovascularization, enhance chemokine production to accelerate inflammatory responses, boost antimicrobial responses to reduce infection, and facilitate tissue remodeling. 15, 16 All these functions are considered critical to normal cutaneous wound repair. IL-22 induces the hepatic production of lipopolysaccharide (LPS)-binding protein (LBP), which inhibits systemic inflammation induced by LPS. 6 Through all of these protective mechanisms, IL-22 has demonstrated efficacy in various murine models of colitis, 7, 8, 12, 17, 19 hepatitis, 20 and pneumonitis. 21 As a result of its potential beneficial effects on innate immunity and regenerative and protective mechanisms in epithelial tissuesexpressing IL-22R, 2, 5, 14, 16 an IL-22 fusion protein is being evaluated as a potential therapeutic in treating epithelial tissue injury. We 
| MATERIALS AND METHODS

| In vitro
| Statistical analysis
Student's two-tailed t-test with Welch's correction was used to compare data between two groups; P < 0.05 was considered statistically significant.
| In vivo
All animal studies were conducted at contract research organization laboratories (details for each study are given below) according to Following sample collection on Day 16, the surviving animals were observed for 7 days and then transferred to the testing facility's training colony. 
| Wounded minipig model study
| Monkeys
Two GLP toxicity studies were conducted in cynomolgus monkeys.
| 11-week study
This study was conducted at Charles River Laboratories in Reno, NV.
UTTR1147A was administered to 5 male and 5 female cynomolgus monkeys once every 2 weeks, for a total of 6 doses, by intravenous IV injection for 11 weeks at 0, 15, 75, or 300 μg/kg and by SC injection at 0 or 75 μg/kg. However, 2 males and 2 females from each group were assessed for reversibility of any drug-related effects over an 8-week recovery period. The doses selected for this study were based on preliminary tolerability data from a pilot 2-week toxicity study (data not shown) as well as the projected human efficacious dose of 25 μg/kg (based on the 0.03 mg/kg efficacious dose in the mouse DSS colitis model; 19 In addition, a subset of animals (2M/2F) from all dose groups were observed for an additional period of 8 weeks following the final dose (i.e., treatment-free recovery period)
to assess the reversibility of toxicity and PD biomarker effects. 
| Chronic 6-month study
This study conducted at Covance Laboratories in Muenster, Germany. UTTR1147A was administered to 5 sexually mature male and 5 sexually mature female cynomolgus monkeys by IV injection Q2W
for a total of 14 doses over 26 weeks at 0, 30, 100, and 300 μg/kg.
As in the 11-week study, 2 males and 2 females per group were assessed for reversibility of any drug-related effects over a 12-week recovery period. These doses were selected based on the results of the previous 11-week study where we observed minimal findings starting at 75 μg/kg. 3 | RESULTS
| In vitro STAT3 activation in primary hepatocytes
Sequence homology in IL-22 and IL-22Ra1 protein across species is shown in Figure A1 . The percent identity of the nonclinical species to human IL22 and IL22Ra1 ranges from 75% to 95% and 71% to 88%, respectively (Table A1, A representative Western blot image is shown in Figure 1 .
UTTR1147A-induced STAT3 phosphorylation in primary hepatocytes from human, cynomolgus monkey, minipig, and mouse was observed after incubation with UTTR1147A at 0.5 μg/mL for 30 minutes. To achieve similar level of STAT3 phosphorylation in rat hepatocytes, higher concentrations of UTTR1147A (5 and 50 μg/mL) and longer incubations (30 minutes and 24 hours) were required.
Densitometric quantification of these blots is presented in Figure A2 . The results illustrate the ability of UTTR1147A in activating STAT3 phosphorylation after engaging IL-22 receptors on hepatocytes from all tested species, albeit with rat needing higher concentrations. Based on these data, studies proceeded with rat, minipig, and cynomolgus monkeys as appropriate nonclinical species for the in vivo translational safety assessment of UTTR1147A. Rats tolerated the repeated administration in this study with no significant weight loss and no neurobehavioral and ophthalmic abnormalities over the period of study (data not shown). The only UTTR1147A-related finding was reversible, minimal to mild epidermal hyperplasia in the highest dose group (1500 μg/kg; Figure 2 ).
While fibrinogen and CRP elevations were considered a direct downstream pharmacological effect of IL-22R activation, the rats did not exhibit increases in these acute phase proteins as rats typically use different acute phase response pathways, which were not tested 23 (Table 1) .
Overall, based on the toxicity finding of epidermal hyperplasia in the high-dose group given 1500 μg/kg, the no-observable adverse effect level (NOAEL) was determined to be 150 μg/kg. 
| Repeat dose toxicity studies in cynomolgus monkeys
Cynomolgus monkeys are considered an appropriate nonrodent species for the safety assessment of biotherapeutics, based on their relevance to antigen-binding and pharmacologic response. 18 Additionally, the in vitro hepatocyte data demonstrating STAT3 activation in response to UTTR1147A (Figure 1 ) provided a strong rationale that the cynomolgus monkeys would provide relevant translatable information on the impact of systemic IL-22 pathway activation. To be able to support First-in-Human (FIH) entry and a clinical dosing regimen of 6-12 weeks and beyond, UTTR1147A was administered to cynomolgus monkeys in 2 separate studies.
In the 11-week study, there were no UTTR1147A-related changes in body weights or other endpoints evaluated. Additionally, there were no toxicologically relevant changes in cardiovascular, respiratory, or neurologic safety pharmacology parameters observed with either IV or SC administration of UTTR1147A (data not shown).
However, UTTR1147A-related findings were limited to cutaneous erythema at 300 μg/kg, which correlated with the microscopic finding of epidermal hyperplasia at 75 μg/kg (SC) and 300 μg/kg (IV) ( Figure 3A ), these were the expected pharmacologic effects of UTTR1147A. These observations were trending toward recovery (clinical signs) or had fully recovered (microscopic findings) by the end of the 12-week dose-free period (data not shown).
While five of 40 animals (13%) given UTTR1147A developed antidrug antibodies (ADAs) after dosing (Table 1) , there was no obvious impact of ADAs on the exposure of UTTR1147A. The exposure of the males was slightly higher than for the females at all dose levels, but did not differ substantially. There was less than 2fold accumulation noted following repeat IV or SC dosing every 2 weeks and TK was roughly linear and dose proportional at these doses ( Figure A3 ).
Ex vivo treatment of mouse colon with IL-22 upregulates the murine REG3 gene isoforms, REG3β, and REG3γ. 5 We evaluated REG3A, the closest-related NHP/human isoform of rodent REG3β, as an exploratory PD biomarker in cynomolgus monkeys. REG3A is an antimicrobial protein produced by the intestinal epithelial cells and pancreatic acinar cells. 25, 26 Increases in REG3A levels were sustained through the dosing period after each dose administration of UTTR1147A ≥ 75 μg/kg and returned to levels similar to control within 2 weeks after the last dose at all dose levels for IV dose F I G U R E 2 H&E stained sections of skin obtained from 1500 μg/ kg UTTR1147A-treated rats on Study Day 78 show a thickening of the epidermal layer, compared to skin from control rats. The observed epidermal hyperplasia was reversed by the end of the 8-week recovery period (data not shown) groups ( Figure 3B ). Alterations in REG3A did not persist past the first dose cycle for the SC dose group, compared to the IV dose group at 75 μg/kg, presumably due to lower exposure (C max and AUC; Table 1 ) in the SC dose group. The dose of 300 μg/kg IV, where we observed sustained elevation in REG3A, was the only dose to produce a C max above the EC50 for pSTAT in human hepatocytes (~3 μg/mL).
At doses ≥75 μg/kg, there were also UTTR1147A-related increases in the levels of the acute phase proteins fibrinogen and CRP with complete reversibility (Table 1 ). There were no increases in systemic levels of proinflammatory cytokines or chemokines (data not shown), demonstrating that UTTR1147A was not activating inflammatory pathways that might indirectly induce CRP such as IL-6 but rather the observed elevations were on-target dosedependent increases as a result of UTTR1147A binding to the IL-22R.
Based on a lack of the adverse effects of skin toxicity, the NOAEL following UTTR1147A administration was considered to be the lowest dose of 15 μg/kg IV (C max /AUC 0t of 188 ng/mL/333 ng·day/mL; Table 1 ).
In a chronic toxicity study in cynomolgus monkeys designed to support longer-term dosing in humans, the only UTTR1147A-related effect in this study was cutaneous erythema and the correlating microscopic finding of epidermal hyperplasia at the dose level of 300 μg/kg at terminal necropsy (data not shown). Affected animals at this dose level also had increased serum fibrinogen levels, consistent with an acute phase response (Table 1) . Both the skin findings and the elevated fibrinogen levels were fully reversed following a 12-week recovery period.
Dose-dependent elevations in the serum PD biomarker REG3A followed the first dose administration at doses ≥100 μg/kg (Table 1) , confirming the pharmacologic activity of UTTR1147A and suggested that IL-22R engagement was achieved at these dose levels. Levels of REG3A appeared to correlate with serum levels of UTTR1147A, and returned to baseline levels by the end of the 12-week recovery period.
We used sexually mature monkeys in the chronic toxicity study, and thus were also able to assess the impact of UTTR1147A on sexual reproduction endpoints. There were no effects of UTTR1147A observed on male and female reproductive endpoints (testicular and semen evaluation; menstrual cyclicity, and ovarian and uterus maturation stage) and there were no UTTR1147A-related macroscopic and microscopic findings in the male and female reproductive organs (data not shown).
In contrast to the 11-week toxicity study, there was a higher rate of ADA formation in in the 26-week study, and the formation of Based on these observations and under these study conditions, the NOAEL was determined to be the mid-dose level of 100 μg/kg every 2 weeks (steadystate C max and steady-state AUC tau of 1900 ng/mL and 8760 ng·day/mL, respectively; Table 1 ) for 26 weeks in this study.
T A B L E 1 A summary of toxicologic, toxicokinetic, and pharmacodynamic parameters from the various toxicity studies is presented here 
| Toxicity studies in minipigs
Due to the anatomic similarity in human and pig skin, the minipig was selected as an appropriate nonclinical species to assess the local toxicity of either a subcutaneous injection or topical administration of UTTR1147A.
In the local subcutaneous study, UTTR1147A-related, dosedependent microscopic findings in the skin at the injection site were observed at 930 and 4660 μg and were characterized by epidermal hyperplasia in both dose groups with the additional findings of epidermal melanosis and increased vascular profiles and a perivascular lymphoplasmacytic infiltrate in the superficial dermis in the 4660 μg dose group, 27 similar to the skin findings observed in the cynomolgus monkeys ( Figure 3A ).
UTTR1147A was well tolerated locally and systemically up to an absolute dose of 4660 μg. The C max and exposure of UTTR1147A
were roughly dose proportional across the dose levels tested
[930 μg (109 ng/mL and 434 ng/mL) and 4660 μg (929 day·ng/mL and 3790 day·ng/mL); Table 1 ] and correlated with the dose-dependent severity and incidence in microscopic skin findings.
Based on the expected pharmacologic findings of IL-22 on the skin, consistent with the other nonclinical species tested, we were also interested in assessing the local tolerability of UTTR1147A in a minipig wound model, which would enable another route of administration in humans.
In the wound-healing minipig model, UTTR1147A did not impair the normal wound healing process ( Figure 4A shows Study Day 11
clinical observations), whereby all wounds were closed and healed by the end of the study (data not shown). UTTR1147A was only detected in the serum of 2 animals in the high dose group (Table 1) .
This increase in systemic exposure corresponded with slight elevations in the levels of the systemic biomarker serum amyloid protein A (SAA) in a few individual animals ( Figure 4B ), suggesting target engagement of the IL-22 pathway in this model.
Overall, topical administration of UTTR1147A to full-thickness dermal wounds was well tolerated and caused no adverse effects.
| DISCUSSION
Nonclinical studies with UTTR1147A have demonstrated a positive benefit to risk ratio in the use of this molecule for the treatment of inflammatory and infectious diseases. Key safety risks are related to expected pharmacologic activity in vivo, including acute phase protein responses and skin toxicity. All UTTR1147A-related findings were consistent with the expected pharmacologic effect of activating the IL-22 pathway, given that IL-22Ra1 is expressed on a variety of epithelial tissues, including epidermal keratinocytes, gastrointestinal tract epithelium, liver hepatocytes, pancreatic epithelium, and renal tubular epithelium. Elevated CRP and fibrinogen are consistent with activating the IL22 pathway in liver hepatocytes, 6, 24 and elevated REG3A is consistent with activating the IL22 pathway in intestinal and pancreatic acinar epithelial cells. 5, 25, 26 In contrast to the cynomolgus monkeys, rats did not exhibit increases in CRP and fibrinogen levels as rats utilize a different acute-phase response than monkeys. 23 Results from the monkey studies demonstrated that serum REG3A levels were increased, and correlated with UTTR1147A drug levels. These data demonstrate pharmacological activity of UTTR1147A and suggest that IL22R engagement was achieved. While the functional aspects of the increase in REG3A in cynomolgus monkeys given UTTR1147A
were not explored in the toxicity studies reported here, systemic administration of recombinant REG3γ, a murine homologue of Doses of 75 μg/kg and above in monkey studies presented here produced C max at or above the in vitro and in vivo EC50 level estimated from human hepatocytes (~3 μg/mL) and cynomolgus monkeys (~1 μg/mL), respectively. 19 In general, the doses of IL-22Fc required to elicit measurable serum biomarker elevations in healthy mice and monkeys (muIL-22Fc or UTTR1147A, respectively) were associated with a serum C max above 1 μg/mL and these biomarkers returned to baseline when serum levels were below the 10-100 ng/mL range. 19 However, diseased animals may have different levels and/or turnover of IL-22 such that different concentrations of IL-22Fc are required in order to induce pharmacological activity compared to healthy animals.
The low systemic exposure of UTTR1147A in the minipig wound model indicated that either the systemic absorption or bioavailability of UTTR1147A through topical administration to the wound was minimal or that the total dose administered was too low for systemic detection. This could be beneficial to indications where local IL-22 is deficient at sites of injury and is needed for tissue repair.
There were no increases in systemic levels of proinflammatory cytokines or chemokines in nonclinical studies conducted in cynomolgus monkeys. These findings are consistent with IL-22Ra1 expression being limited to epithelial tissues, and no expression of IL-22Ra1 on leukocytes, including T lymphocytes. These findings have also translated clinically, in that UTTR1147A administration in humans has not elicited a proinflammatory cytokine response at the given doses. 20 In summary, results from these nonclinical studies demonstrate the cross-species translatability of the biological response in activating the IL-22 pathway as well as the translatability of findings from in vitro to in vivo systems. Thus, the toxicology program has appropriately identified relevant toxicities associated with UTTR1147A as reversible, minimal to mild epidermal hyperplasia with minimal inflammation, and a reversible acute-phase inflammatory response.
All toxicities are considered monitorable, manageable, and reversible;
and have reliably translated to the toxicities observed in humans in ongoing clinical trials. 22 Lastly, it is also important to note, that depending on the tissue environment in which IL-22 is being upregulated, the functional consequence of activating the IL-22 pathway can lead to either further inflammation or tissue repair. 11 More recently, contributions of understanding of the translatability of animal models to human disease.
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